Showing 1 - 5 results of 5 for search 'Humberto Erick De La Torre Tarazona', query time: 0.03s Refine Results
  1. 1
    Elite controllers long-term non progressors present improved survival and slower disease progression

    Elite controllers long-term non progressors present improved survival and slower disease progression by Laura Capa, Rubén Ayala-Suárez, Humberto Erick De La Torre Tarazona, Juan González-García, Jorge del Romero, José Alcamí, Francisco Díez-Fuertes

    Published 2022-09-01
    Get full text
    Article
  2. 2
    Insight in miRNome of Long-Term Non-Progressors and Elite Controllers Exposes Potential RNAi Role in Restraining HIV-1 Infection

    Insight in miRNome of Long-Term Non-Progressors and Elite Controllers Exposes Potential RNAi Role in Restraining HIV-1 Infection by Rubén Ayala-Suárez, Francisco Díez-Fuertes, Esther Calonge, Humberto Erick De La Torre Tarazona, María Gracia-Ruíz de Alda, Laura Capa, José Alcamí

    Published 2020-07-01
    Get full text
    Article
  3. 3
    Novel association of five HLA alleles with HIV-1 progression in Spanish long-term non progressor patients.

    Novel association of five HLA alleles with HIV-1 progression in Spanish long-term non progressor patients. by Eva Ramírez de Arellano, Francisco Díez-Fuertes, Francisco Aguilar, Humberto Erick de la Torre Tarazona, Susana Sánchez-Lara, Yolanda Lao, José Luis Vicario, Felipe García, Juan González-Garcia, Federico Pulido, Félix Gutierrez-Rodero, Santiago Moreno, Jose Antonio Iribarren, Pompeyo Viciana, Carlos Vilches, Manuel Ramos, Laura Capa, José Alcamí, Margarita Del Val

    Published 2019-01-01
    Get full text
    Article
  4. 4
    Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study

    Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT1... by Ana Ascaso-del-Rio, Javier García-Pérez, Mayte Pérez-Olmeda, Eunate Arana-Arri, Itziar Vergara, Carla Pérez-Ingidua, Mercedes Bermejo, María Castillo de la Osa, Natale Imaz-Ayo, Ioana Riaño Fernández, Oliver Astasio González, Francisco Díez-Fuertes, Susana Meijide, Julio Arrizabalaga, Lourdes Hernández Gutiérrez, Humberto Erick de la Torre-Tarazona, Alberto Mariano Lázaro, Emilio Vargas-Castrillón, José Alcamí, Antonio Portolés

    Published 2022-09-01
    Get full text
    Article
  5. 5
    Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study

    Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study by Javier García-Pérez, María González-Pérez, María Castillo de la Osa, Alberto M. Borobia, Luis Castaño, María Jesús Bertrán, Magdalena Campins, Antonio Portolés, David Lora, Mercedes Bermejo, Patricia Conde, Lourdes Hernández-Gutierrez, Antonio Carcas, Eunate Arana-Arri, Marta Tortajada, Inmaculada Fuentes, Ana Ascaso, María Teresa García-Morales, Humberto Erick de la Torre-Tarazona, José-Ramón Arribas, Natale Imaz-Ayo, Eugènia Mellado-Pau, Antonia Agustí, Carla Pérez-Ingidua, Agustín Gómez de la Cámara, Jordi Ochando, Cristobal Belda-Iniesta, Jesús Frías, José Alcamí, Mayte Pérez-Olmeda

    Published 2022-08-01
    Get full text
    Article

Search Tools: